Diamyd Medical AB has partnered its lead antigen-based therapy for the treatment and prevention of Type1 diabetes with Ortho-McNeil-Janssen Pharmaceuticals Inc (OMJPI), a unit of Johnson & Johnson. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
